Cyclosporine A (CsA) is a potent immunosuppressant with the drawback of ren
al side effects. We reported that CsA markedly decreases calcium-binding pr
otein calbindin-D28k mRNA levels in rat kidneys, and showed that this decre
ase is associated with its adverse renal effects. The transcription of the
calbindin-D28k gene is activated via the vitamin D pathway. In this work, t
he potential CsA-mediated impairment of the vitamin D pathway was investiga
ted. Wistar rats were treated for 12 days with 50 mg/kg/day CsA or for 20 d
ays with 50 mg/kg/day of the non-immunosuppressant and non-nephrotoxic SDZ
PSC 833, which had been previously shown not to affect calbindin-D28k mRNA
levels. The expression of the three vitamin D-regulated genes calbindin-D28
k, 1,25-dihydroxyvitamin D-3-24-hydroxylase (24- OHase), and vitamin D rece
ptor (VDR) were quantified in rat kidney homogenates by real-time reverse t
ranscription-polymerase chain reaction. Plasma parathyroid hormone (PTH) as
well as plasma and kidney 1,25 dihydroxyvitamin D-3 (calcitriol) levels we
re monitored in all animals. CsA induced a 85% decrease in calbindin-D28k m
RNA levels as well as a 40% and 69% decrease in VDR and 24-OHase mRNA level
s, respectively. Plasma and kidney 1,25 dihydroxyvitamin D-3 as well as pla
sma PTH levels were increased by CsA, but not by SDZ PSC 833. The treatment
with SDZ PSC 833 did not affect calbindin-D28k or VDR expression, but did
cause a 73% decrease in 24-OHase mRNA levels. Taken together, these results
indicate an association between CsA-mediated down-regulation of rat renal
calbindin-D28k mRNA and the decrease in other 1,25 dihydroxyvitamin D-3-reg
ulated genes, suggesting an impairment of the vitamin D pathway by CsA whic
h may be related to its adverse renal side effects and its immunosuppressiv
e activity. (C) 1999 Elsevier Science Inc.